FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis

CRESEMBA is the only azole antifungal therapy approved for pediatric patients as young as one affected by these serious, potentially life-threatening infections Approval based on results of two pediatric studies in children aged 1 to 17 NORTHBROOK, Ill., Dec. 8, 2023 /PRNewswire/ –…